Sabaa Pharmaceutical’s losses widen 940.5% in Q1

Revenues dropped to EGP 1.665 million during the January-March period of this year, from EGP 2.563 million during the first three months of 2023

Staff Writer, Arab Finance

June 2, 2024

PHOTO
A trader works at the Egyptian stock exchange in Cairo. Image for illustrative purposes. Mohamed Abd El Ghany, Reuters

Sabaa International for Pharmaceutical and Chemical Industry (SIPC) incurred net losses after tax of EGP 1.019 million during the first quarter (Q1) of 2024, up by 940.49% from EGP 98,021 in the year-ago quarter, according to the company’s financial statement.

Revenues dropped to EGP 1.665 million during the January-March period of this year, from EGP 2.563 million during the first three months of 2023.

Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

ZAWYA NEWSLETTERS

RELATED ARTICLES

ZAWYA NEWSLETTERS

LATEST VIDEO